Cargando…
Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era
BACKGROUND: Metastatic colorectal cancer patients with deficient mismatch repair (dMMR mCRC) benefit from immunotherapy. Interpretation of the single-arm immunotherapy trials is complicated by insignificant survival data during systemic non-immunotherapy. We present survival data on a large, compreh...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852682/ https://www.ncbi.nlm.nih.gov/pubmed/33046804 http://dx.doi.org/10.1038/s41416-020-01076-0 |
| _version_ | 1783645860977967104 |
|---|---|
| author | Wensink, G. Emerens Elferink, Marloes A. G. May, Anne M. Mol, Linda Hamers, Patricia A. H. Bakker, Sandra D. Creemers, Geert-Jan de Groot, Jan Willem B. de Klerk, Gerty J. Haberkorn, Brigitte C. M. Haringhuizen, Annebeth W. Hoekstra, Ronald Hunting, J. Cornelis B. Kerver, Emile D. Mathijssen-van Stein, Danielle Polée, Marco B. Pruijt, Johannes F. M. Quarles van Ufford-Mannesse, Patricia Radema, Sandra Rietbroek, Ronald C. Simkens, Lieke H. J. Tanis, Bea C. ten Bokkel Huinink, Daan Tjin-A-Ton, Manuel L. R. Tromp-van Driel, Cathrien S. Troost, Monique M. van de Wouw, Agnes J. van den Berkmortel, Franchette W. P. J. van der Pas, Anke J. M. van der Velden, Ankie M. T. van Dijk, Marjan A. van Dodewaard-de Jong, Joyce M. van Druten, Edith B. van Voorthuizen, Theo Jan Veldhuis, Gerrit Verheul, Henk M. W. Vestjens, Hanneke J. H. M. J. Vincent, Jeroen Kranenburg, Onno W. Punt, Cornelis J. A. Vink, Geraldine R. Roodhart, Jeanine M. L. Koopman, Miriam |
| author_facet | Wensink, G. Emerens Elferink, Marloes A. G. May, Anne M. Mol, Linda Hamers, Patricia A. H. Bakker, Sandra D. Creemers, Geert-Jan de Groot, Jan Willem B. de Klerk, Gerty J. Haberkorn, Brigitte C. M. Haringhuizen, Annebeth W. Hoekstra, Ronald Hunting, J. Cornelis B. Kerver, Emile D. Mathijssen-van Stein, Danielle Polée, Marco B. Pruijt, Johannes F. M. Quarles van Ufford-Mannesse, Patricia Radema, Sandra Rietbroek, Ronald C. Simkens, Lieke H. J. Tanis, Bea C. ten Bokkel Huinink, Daan Tjin-A-Ton, Manuel L. R. Tromp-van Driel, Cathrien S. Troost, Monique M. van de Wouw, Agnes J. van den Berkmortel, Franchette W. P. J. van der Pas, Anke J. M. van der Velden, Ankie M. T. van Dijk, Marjan A. van Dodewaard-de Jong, Joyce M. van Druten, Edith B. van Voorthuizen, Theo Jan Veldhuis, Gerrit Verheul, Henk M. W. Vestjens, Hanneke J. H. M. J. Vincent, Jeroen Kranenburg, Onno W. Punt, Cornelis J. A. Vink, Geraldine R. Roodhart, Jeanine M. L. Koopman, Miriam |
| author_sort | Wensink, G. Emerens |
| collection | PubMed |
| description | BACKGROUND: Metastatic colorectal cancer patients with deficient mismatch repair (dMMR mCRC) benefit from immunotherapy. Interpretation of the single-arm immunotherapy trials is complicated by insignificant survival data during systemic non-immunotherapy. We present survival data on a large, comprehensive cohort of dMMR mCRC patients, treated with or without systemic non-immunotherapy. METHODS: Two hundred and eighty-one dMMR mCRC patients (n = 54 from three prospective Phase 3 CAIRO trials; n = 227 from the Netherlands Cancer Registry). Overall survival was analysed from diagnosis of mCRC (OS), from initiation of first-line (OS1) and second-line (OS2) systemic treatment. Cox regression analysis examined prognostic factors. As comparison for OS 2746 MMR proficient mCRC patients were identified. RESULTS: Of 281 dMMR patients, 62% received first-line and 26% second-line treatment. Median OS was 16.0 months (13.8–19.6) with antitumour therapy and 2.5 months (1.8–3.5) in untreated patients. OS1 was 12.8 months (10.7–15.2) and OS2 6.2 months (5.4–8.9) in treated dMMR patients. Treated dMMR patients had a 7.6-month shorter median OS than pMMR patients. CONCLUSION: Available data from immunotherapy trials lack a control arm with standard systemic treatment. Given the poor outcome compared to the immunotherapy results, our data strongly suggest a survival benefit of immunotherapy in dMMR mCRC patients. |
| format | Online Article Text |
| id | pubmed-7852682 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78526822021-10-13 Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era Wensink, G. Emerens Elferink, Marloes A. G. May, Anne M. Mol, Linda Hamers, Patricia A. H. Bakker, Sandra D. Creemers, Geert-Jan de Groot, Jan Willem B. de Klerk, Gerty J. Haberkorn, Brigitte C. M. Haringhuizen, Annebeth W. Hoekstra, Ronald Hunting, J. Cornelis B. Kerver, Emile D. Mathijssen-van Stein, Danielle Polée, Marco B. Pruijt, Johannes F. M. Quarles van Ufford-Mannesse, Patricia Radema, Sandra Rietbroek, Ronald C. Simkens, Lieke H. J. Tanis, Bea C. ten Bokkel Huinink, Daan Tjin-A-Ton, Manuel L. R. Tromp-van Driel, Cathrien S. Troost, Monique M. van de Wouw, Agnes J. van den Berkmortel, Franchette W. P. J. van der Pas, Anke J. M. van der Velden, Ankie M. T. van Dijk, Marjan A. van Dodewaard-de Jong, Joyce M. van Druten, Edith B. van Voorthuizen, Theo Jan Veldhuis, Gerrit Verheul, Henk M. W. Vestjens, Hanneke J. H. M. J. Vincent, Jeroen Kranenburg, Onno W. Punt, Cornelis J. A. Vink, Geraldine R. Roodhart, Jeanine M. L. Koopman, Miriam Br J Cancer Article BACKGROUND: Metastatic colorectal cancer patients with deficient mismatch repair (dMMR mCRC) benefit from immunotherapy. Interpretation of the single-arm immunotherapy trials is complicated by insignificant survival data during systemic non-immunotherapy. We present survival data on a large, comprehensive cohort of dMMR mCRC patients, treated with or without systemic non-immunotherapy. METHODS: Two hundred and eighty-one dMMR mCRC patients (n = 54 from three prospective Phase 3 CAIRO trials; n = 227 from the Netherlands Cancer Registry). Overall survival was analysed from diagnosis of mCRC (OS), from initiation of first-line (OS1) and second-line (OS2) systemic treatment. Cox regression analysis examined prognostic factors. As comparison for OS 2746 MMR proficient mCRC patients were identified. RESULTS: Of 281 dMMR patients, 62% received first-line and 26% second-line treatment. Median OS was 16.0 months (13.8–19.6) with antitumour therapy and 2.5 months (1.8–3.5) in untreated patients. OS1 was 12.8 months (10.7–15.2) and OS2 6.2 months (5.4–8.9) in treated dMMR patients. Treated dMMR patients had a 7.6-month shorter median OS than pMMR patients. CONCLUSION: Available data from immunotherapy trials lack a control arm with standard systemic treatment. Given the poor outcome compared to the immunotherapy results, our data strongly suggest a survival benefit of immunotherapy in dMMR mCRC patients. Nature Publishing Group UK 2020-10-13 2021-01-19 /pmc/articles/PMC7852682/ /pubmed/33046804 http://dx.doi.org/10.1038/s41416-020-01076-0 Text en © The Author(s), under exclusive licence to Cancer Research UK 2020 https://creativecommons.org/licenses/by/4.0/ Note This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0). |
| spellingShingle | Article Wensink, G. Emerens Elferink, Marloes A. G. May, Anne M. Mol, Linda Hamers, Patricia A. H. Bakker, Sandra D. Creemers, Geert-Jan de Groot, Jan Willem B. de Klerk, Gerty J. Haberkorn, Brigitte C. M. Haringhuizen, Annebeth W. Hoekstra, Ronald Hunting, J. Cornelis B. Kerver, Emile D. Mathijssen-van Stein, Danielle Polée, Marco B. Pruijt, Johannes F. M. Quarles van Ufford-Mannesse, Patricia Radema, Sandra Rietbroek, Ronald C. Simkens, Lieke H. J. Tanis, Bea C. ten Bokkel Huinink, Daan Tjin-A-Ton, Manuel L. R. Tromp-van Driel, Cathrien S. Troost, Monique M. van de Wouw, Agnes J. van den Berkmortel, Franchette W. P. J. van der Pas, Anke J. M. van der Velden, Ankie M. T. van Dijk, Marjan A. van Dodewaard-de Jong, Joyce M. van Druten, Edith B. van Voorthuizen, Theo Jan Veldhuis, Gerrit Verheul, Henk M. W. Vestjens, Hanneke J. H. M. J. Vincent, Jeroen Kranenburg, Onno W. Punt, Cornelis J. A. Vink, Geraldine R. Roodhart, Jeanine M. L. Koopman, Miriam Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era |
| title | Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era |
| title_full | Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era |
| title_fullStr | Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era |
| title_full_unstemmed | Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era |
| title_short | Survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era |
| title_sort | survival of patients with deficient mismatch repair metastatic colorectal cancer in the pre-immunotherapy era |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852682/ https://www.ncbi.nlm.nih.gov/pubmed/33046804 http://dx.doi.org/10.1038/s41416-020-01076-0 |
| work_keys_str_mv | AT wensinkgemerens survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT elferinkmarloesag survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT mayannem survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT mollinda survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT hamerspatriciaah survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT bakkersandrad survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT creemersgeertjan survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT degrootjanwillemb survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT deklerkgertyj survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT haberkornbrigittecm survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT haringhuizenannebethw survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT hoekstraronald survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT huntingjcornelisb survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT kerveremiled survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT mathijssenvansteindanielle survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT poleemarcob survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT pruijtjohannesfm survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT quarlesvanuffordmannessepatricia survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT rademasandra survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT rietbroekronaldc survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT simkensliekehj survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT tanisbeac survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT tenbokkelhuininkdaan survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT tjinatonmanuellr survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT trompvandrielcathriens survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT troostmoniquem survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT vandewouwagnesj survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT vandenberkmortelfranchettewpj survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT vanderpasankejm survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT vanderveldenankiemt survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT vandijkmarjana survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT vandodewaarddejongjoycem survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT vandrutenedithb survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT vanvoorthuizentheo survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT janveldhuisgerrit survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT verheulhenkmw survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT vestjenshannekejhmj survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT vincentjeroen survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT kranenburgonnow survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT puntcornelisja survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT vinkgeraldiner survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT roodhartjeanineml survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera AT koopmanmiriam survivalofpatientswithdeficientmismatchrepairmetastaticcolorectalcancerinthepreimmunotherapyera |